(IN BRIEF) The Institute of Cancer Research, London, has presented encouraging results from the phase Ib/II OrigAMI-4 clinical trial, showing that the targeted immunotherapy drug amivantamab shrank tumours in 42 per cent of patients with recurrent and/or metastatic head and … Read the full press release →
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged American Society of Clinical Oncology, amivantamab, Amivantamab Demonstrates Encouraging Survival and Tumour Shrinkage Outcomes in Hard-to-Treat Head and Neck Cancer Patients, ASCO Annual Meeting, bispecific monoclonal antibody, cancer research, Carl Walsh, clinical trial, complete response, EGFR, head and neck squamous cell carcinoma, HNSCC, ICR, immunotherapy, Johnson & Johnson, Met, metastatic head and neck cancer, oncology, OrigAMI-4, OrigAMI-5, outpatient cancer treatment, partial response, phase Ib II trial, Phase III Trial, platinum-based chemotherapy, Professor Kevin Harrington, Professor Kristian Helin, recurrent head and neck cancer, Subcutaneous Injection, targeted cancer treatment, Targeted Immunotherapy Injection Shows Strong Clinical Activity in Patients with Treatment-Resistant Head and Neck Cancer, The Institute of Cancer Research and Royal Marsden Team Advance Clinical Evidence for Injectable Head and Neck Cancer Treatment, The Institute of Cancer Research London, The Royal Marsden NHS Foundation Trust, treatment-resistant cancer, tumour shrinkage
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?
Load more...
| M | T | W | T | F | S | S |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| 15 | 16 | 17 | 18 | 19 | 20 | 21 |
| 22 | 23 | 24 | 25 | 26 | 27 | 28 |
| 29 | 30 | |||||
